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Abstract
The cornerstone of therapy in thromboangiitis obliterans (TAO) is complete abstinence from tobacco. In addition to discontinuation of
cigarette smoking, very few pharmacological and surgical options of controversial efficacy are available to date. New therapeutic
options with greater efficacy are clearly needed to properly manage these patients.
In this preliminary study, we assessed the effectiveness and safety of bosentan in a case series of 8 adults with TAO and severe
ischemic ulceronecrotic lesions who were treated with bosentan after inadequate response to platelet inhibitors, vasodilators, and
intravenous alprostadil. Additionally, we reviewed 18 well-documented patients with refractory TAO treated with bosentan, which
was previously reported (PubMed 1965–2015). These 26 patients formed the basis of our present analysis. All were current smokers.
The median duration of bosentan treatment (SD) was 4.5±4 months (range 3–16). Eleven patients (42%) were unable to
completely abstain from smoking during their follow-up. With bosentan treatment, no new ischemic lesions were observed in the
target extremities. A complete therapeutic response was achieved in 80% of patients, whereas a partial response was observed in
12%. Two patients (8%) ultimately required amputation despite treatment.
After discontinuation of bosentan, patients were followed for amedian of 20±14months (range 3–60). Two patients whose trophic
lesions had healed relapsed.
When comparing patients who gave up smoking with those who were unable to completely abstain from smoking during follow-
up, no significant differences were found in efficacy outcomes. Four patients (15%) developed adverse events, requiring bosentan
discontinuation in 1 case.
These preliminary data suggest that bosentan may be considered a therapeutic option for treatment of cases of severe TAO
refractory to conventional treatment, and merit further evaluation in larger controlled, randomized clinical studies.
Abbreviations: BAFMD= brachial artery flow-mediated dilation test, ET = endothelin, IL= interleukin, MRI =magnetic resonance
imaging, PGE-1 = intravenous alprostadil, TAO = thromboangiitis obliterans.
Keywords: bosentan, Buerger disease, effectiveness, safety, thromboangiitis obliterans1. Introduction
Thromboangiitis obliterans (TAO) or Buerger disease is a distinct
form of systemic vasculitis of unknown etiology, though strongly
linked to cigarette smoking.[1,2] It affects the small and medium-
sized arteries and veins in the upper and lower extremities.Editor: Raouf Hajji.
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rest, and ultimately result in the development of ischemic
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the discontinuation of tobacco, very few pharmacological and
surgical options of controversial efficacy are available to date.
Different treatments such as antiplatelet agents, anticoagulants,
and vasodilators (including calcium channel blockers, pentoxyfyl-
line, and cilostazol) are widely used, although there is no proven
evidence of their palliative benefits.[3,4] Prostaglandin analogs are
beneficial when administered intravenously, although they are no
better than placebo on oral administration, and the beneficial
effects are transient and disappear after treatment is stopped.[3]
Surgical techniques (revascularization, sympathectomy, Ilizavor
technique, and omentopexy omentum autografts) are limited in
scope and usefulness.[4] New therapeutic options with greater
efficacy are clearly needed to properly manage these patients.
Endothelial dysfunction appears to be of relevance in
TAO,[5–7] and an increase in the level of endothelin 1 (ET-1)—
a potent vasoconstrictor—has been observed in patients with
clinically active disease and necrotic lesions.[8] Based on these
findings, bosentan—a competitive antagonist of ET-1 at the
endothelin-A (ET-A) and endothelin-B (ET-B) receptors—is
beginning to be used in severe and refractory cases of TAO,
and has effectiveness and a good safety profile.[9–15]
In this preliminary study, we assessed the effectiveness and
safety of bosentan in a case series of patients with severe TAO
refractory to conventional treatment, including platelet inhib-
itors, vasodilators (calcium channel blocker and/or pentoxyfyl-
line), and intravenous prostaglandins. Current evidence of the
therapeutic use of bosentan in this complex situation was also
analyzed through a systematic review of the literature.2. Patients and methods
2.1. Patient selection
The sample included eight patients with TA recruited at three
hospitals in Barcelona (Spain), all fullfiling the diagnostic criteria
proposed by Olin et al[1,2] and Shinoya et al[16]: onset before the
age of 50 years; current (or recent past) tobacco use; distal
extremity ischemia (infrapopliteal and/or intrabrachial), such as
claudication, rest pain, ischemic ulcers, and gangrene docu-
mented with noninvasive testing; exclusion of connective tissue
diseases and hypercoagulable states; exclusion of a proximal
source of emboli with echocardiography and arteriography; and
consistent arteriographic findings in the involved and clinically
uninvolved limbs including multiple segmental occlusions of
distal arterial sections (distally from the elbow and knee); chronic
vascular occlusion due to secondary thrombosis; absence of
atherosclerotic lesions, such as calcification of vascular walls;
tapering and abrupt obstruction of vessels, a twisting course of
the involved vessels; and “corkscrew” or “tree-root” collaterals.
Patients were selected to be treated with bosentan if they met
the following inclusion criteria: severe distal extremity ischemia
with nonhealing ulceronecrotic lesions present for at least 4
weeks and with inadequate response to conventional treatment,
including platelet inhibitors (aspirin or clopidogrel), vasodilators
(calcium channel blocker and pentoxyfylline), and intravenous
alprostadil (PGE-1) for 21 days; and non-candidates for surgical
or endovascular revascularization of the extremity studied.
A clinical pilot, open-label, uncontrolled, prospective study was
designed in which these patients received treatment with bosentan
in a compassionate use program. Informed consent was obtained
from each patient, and their clinical records were anonymized and
de-identified before analysis. The study was approved by our2
institutional ethics committee and was conducted in accordance
with the principles of the Declaration of Helsinki and the
International Conference for Harmonization.
All patients received bosentan p.o. at a dose of 62.5mg twice
daily during the first month, which was thereafter up-titrated to
125mg twice daily each month if significant adverse events
attributable to bosentan were ruled out. This full-dose regimen
(125mg/12h) was maintained until complete healing of the distal
ischemic trophic lesions was achieved, provided that the liver
function tests and blood cell counts remained within the normal
ranges. Concomitantmedicationwith platelet inhibitors (aspirin or
clopidogrel) and vasodilators (calcium channel blocker and/or
pentoxyfylline) was maintained at the discretion of the referring
physician. Patients were given analgesic treatment as necessary to
control pain at rest. The ischemic lesions and necrotic ulcers were
treatedwith standarddaily care andantibiotic therapyasnecessary.
Inpatient and outpatient charts were comprehensively
reviewed following a specifically designed protocol that
addressed smoking status during the study period, efficacy data
(evolution of ischemic pain and trophic lesions, presence/absence
of major or minor amputation), and safety data (tolerability and
side effect profile of bosentan). The endpoint of patient follow-up
was the date of the last clinic visit. The study endpoints were
clinical improvement rate, the need for amputation (major or
minor), and the occurrence of relapses. Complete therapeutic
response was defined as the complete healing of the distal
ulceronecrotic lesions with disappearance of ischemic pain.
Partial response was considered in cases with significant
improvement of ulceronecrotic lesions without complete healing.2.2. Literature search strategy and selection criteria
In addition to our case series, we analyzed current evidence on
the therapeutic use of bosentan in patients with TAO using a
systematic review of reports published in indexed international
journals (not reviews, congress abstracts, or unpublished
results). Searches were conducted in the PubMed database
(ie, including MEDLINE, National Library of Medicine, and
PubMed Central) for the period between January 1965 and
December 2015 using the strategies recommended by the
Cochrane handbook. Search terms included “bosentan”,
“thromboangiitis obliterans,” and “Buerger disease.” Only
English and Spanish-language reports were selected for review.
The references of the studies obtained were then examined to
identify additional reports.
The MEDLINE search resulted in 9 articles.[4,9–15,17] After
evaluation of the full text, 2 of these articles were excluded
because they were reviews.[4,17] In addition, we excluded 7 of the
19 cases reported by De Haro et al[11] because their clinical
characteristics were not sufficiently detailed to be individually
analyzed.
Therefore, 6 articles were finally selected for review, identifying
18 well-documented cases of patients with TAO refractory to
conventional treatment who were treated with bosentan.2.3. Statistical analysis
Qualitative variables were described by frequencies and percen-
tages, and quantitative variables were described by mean or
median± standarddeviation (SD) and range.Comparisonbetween
groups was made using the chi-square test for categorical data or
the Fisher exact test when the expected values were less than 5.
Statistical significance was defined as P0.05.
Table 1














of bosentan, mos Outcome
45/Women Resting pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d) nifedipine,
pentoxifylline, and AAS
Yes 10 24 Complete response; no
relapses
39/Women Resting pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
and AAS
Yes 13 34 Complete response; no
relapses
48/Men Raynaud phenomenon, resting
pain, and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
and AAS
Yes 11 32 Complete response; no
relapses
47/Men Resting pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
and AAS
Yes 14 33 Complete response; no
relapses
37/Men Resting pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
pentoxifylline, and AAS
Yes 6 Still on treatment Complete response
45/Women Resting pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
and AAS
No 5 Still on treatment Complete response
47/Women Raynaud phenomenon, resting
pain and ulceronecrotic
lesions in several fingers
Alprostadil i.v. (21 d), nifedipine,
pentoxifylline, and clopidogrel
Yes 13 Still on treatment Complete response
34/Men Resting pain and ischemic ulcers
in several fingers and toes,
with extensive digital necrosis
of the second finger of the
right hand that required digital
amputation
Alprostadil i.v. (21 d),
pentoxifylline, and trifusal
No 5 71 Complete response
Transmetacarpal amputation of
the of the second finger of
the right hand
Relapse (ulcers on
several toes) 60 mos
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A total of 8 consecutive patients were included in the study.
Their main clinical characteristics and outcome are summarized
in Table 1. All patients had previously been treated with a 21-
day prostaglandin regimen, platelet inhibitors (aspirin or
clopidogrel), and vasodilators (calcium channel blocker and/
or pentoxyfylline) without significant clinical improvement in
the symptoms or healing of their ischemic ulceronecrotic
lesions.
The main clinical characteristics and outcomes of the 18
patients obtained from the literature are summarized in Table 2.
Including the 8 patients presented here, 26 cases of refractory
TAO treated with bosentan were available for review. The global
analysis of these patients provided the information described
under the following subheadings.
3.1. Demographic data
Of the 26 patients, 16 were men (61.5%) and 10 (38.5%) were
women, with ages ranging from 22 to 72 years (mean 44±11
years). All were current smokers. Two (8%) patients were also
frequent cannabis and cocaine abusers.3.2. Clinical manifestations of TAO
All but 1 patient (96%) presented with distal ischemic ulcers and/
or digital necrosis, generally in the form of necrotic irregular
eschars 1 to 1.5cm in diameter in the pads of the fingers or toes,
or in the periungual areas, and more rarely as an extensive
necrosis and toe gangrene. The remaining patient only had
ischemic pain at rest in the legs with skin integrity at baseline.3
The upper extremities were involved in 50% (13/26) of the
patients, the lower limbs were involved in 38% (10/26), and 12%
(3/26) presented simultaneous involvement of upper and lower
extremities.
Twenty-five patients (96%) had more than 1 ulceronecrotic
lesion in the fingers or toes. Only 1 patient (4%) presented with
lesions on the back of the foot at baseline.
Seven patients (27%) previously had at least 1 episode of
phlebitis migrans, Raynaud phenomenon was present in 2 (8%)
patients, and ischemic intermittent claudication was present in
another 2 (8%).3.3. Previous and concomitant treatments
Before treatment with bosentan, 81% (21/26) of the patients had
previously been treated with intravenous prostaglandins (in all
but 1 case with a 21-day regimen). Antiplatelet drugs were used in
92% (24/26) of the patients, heparin in 8% (2/26), and
vasodilators (calcium channel blocker and/or pentoxyfylline) in
69% (18/26).
Three (12%) of the 26 patients had undergone revascularizing
procedures, 5 (19%) had a previous lumbar or axillary
sympathectomy, and 2 (8%) had required previous minor
amputation.
Eleven patients (42%) were unable to completely abstain from
smoking during the follow-up.3.4. Effectiveness and outcome
The duration of bosentan treatment (median±SD) was 4.5±4
months (range 3–16). At the time of the last follow-up, 4 out of 26
Table 2
Clinical characteristics and outcomes of 18 reported patients with
refractory thromboangiitis obliterans (TAO) treated with bosentan.
Number of patients 18
Age (mean±SD, range), y 44±12 (22–72)
Sex (male/female) 12 (67%)/6 (33%)
Clinical manifestations of TAO
Distal extremity ulceronecrotic lesions 17/18 (94%)
Patients with more than one trophic Lesion in
fingers or toes
17/18 (94%)
Upper extremity involvement 7 (39%)
Lower limb involvement 10 (55%)
Involvement of both upper and limb extremities 1 (6%)
Lesions on the back of the foot 1 (6%)
Ischemic intermittent claudication 2 (11%)
Phlebitis migrans (at least one episode) 7 (39%)
Current smokers 18 (100%)
Give up smoking Yes: 9 (50%)/
no: 9 (50%)
Previous/concomitant treatments
Intravenous prostaglandins 13 (72%)
Platelet inhibitors (aspirin or clopidogrel) 16 (89%)
Heparin 2 (11%)
Vasodilators (calcium channel blocker and pentoxyfylline) 10 (55%)
Previous revascularizing procedures 3 (17%)
Previous lumbar or axillary sympathectomy 4 (22%)
Previous amputation (minor) 1 (6%)
Duration of bosentan treatment (median±SD, range) mos 4±3.5 (3–16 mos)




Complete response 13 (72%)
Partial response 3 (17%)
Amputation 2 (11%) [major: 1/minor: 1]
New ischemic lesions with bosentan treatment 0 (0%)





Adverse events 4 (22%)
Transient edema in the lower extremities 3 (17%)
Serum transaminases elevation 1 (6%)
Discontinuation of bosentan therapy due to adverse event 1 (6%)
The results are presented as the means or medians± standard deviation or the number of cases with
percentages.
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treatment duration of 9±4 months. In the remaining 22 patients,
bosentan therapy was discontinued.
During follow-up with bosentan treatment, no new ischemic
lesions were observed in the target extremities. A complete
therapeutic response was achieved in 80% (21/26) of the patients,
whereas partial response (significant improvement of ulcer-
onecrotic lesions without complete healing) was observed in 12%
(3/26). Two patients (8%) ultimately required amputation
despite treatment (major in 1 case and minor in the other).
In some of these patients, the improvement in distal circulation
was confirmed by objective methods such as digital arteriography
with subtraction, angio-magnetic resonance imaging (MRI) or
angio-TC (12 patients), brachial artery flow-mediated dilation
test (12 patients), nailfold capillaroscopy (2 patients), or digital
plethysmograph (4 patients). In all patients monitored with the
brachial artery flow-mediated dilation test (BAFMD), bosentan
therapy significantly improved their baseline values (mean: 1.8 at
baseline, 6.6 at the end of the bosentan treatment, and 12.7 at 3
months after the end of the treatment; P<0.01).4
After discontinuation of bosentan, patients were followed for a
median of 20±14 months (range 3–60). Two patients whose
trophic lesions had healed relapsed 3 and 60months after the end
of bosentan therapy. In 1 of these cases, a new 4-month course of
bosentan was sufficient to heal the lesions.
When comparing patients who gave up smoking with those
who were unable to completely abstain from smoking during
follow-up, no significant differences were found in the outcome
measures (smoking vs no smoking): complete response 73%
versus 87% (P=0.373); partial response 18% versus 7% (P=
0.364); amputation (major or minor) 9% versus 7% (P=0.819);
and relapses 18% versus 0% (P=0.086).3.5. Safety
Four patients (15%) developed adverse events due to bosentan
therapy: 1 case of serum transaminase elevation leading to
withdrawal of treatment at 3 months and 3 cases of transient
edema in the lower extremities, consistent with the vasodilatory
effect of the distal bed associated with bosentan use.4. Discussion
Despite not being life-threatening, TAO has a poor functional
prognosis, often requiring partial or total surgical limb
amputations. In addition to discontinuation of cigarette smoking,
only intravenous prostaglandin has demonstrated proven
efficacy, but its effect fades upon finishing treatment (21–28
days).[3] More recently, bosentan has been introduced in
refractory cases of TAO, bringing in a new alternative for
prolonged oral treatment.[9–15]
The current evidence for the effectiveness of bosentan in TAO
is based solely on several case reports and 2 small pilot
observational studies, including ours. Although it is not yet
possible to make definite recommendations, the global analysis of
these preliminary data supports the off-label use of bosentan as a
second-line therapy in patients with severe refractory TAO. A
complete therapeutic response was achieved in 80% of these
patients, with an amputation rate (major and minor) of only 8%.
It should be highlighted that this excellent clinical response was
achieved, despite the fact that 42% of the patients continued to
smoke. These results compare favorably with data from previous
studies, which reported an amputation rate of 19% to 65%
among the patients who continued to smoke.[18,19]
Of interest, the clinical improvement was accompanied by a
significant improvement in distal circulation confirmed by
objective methods such as imaging techniques (digital arteriog-
raphy, angio-MRI, or angio-TC),[11–14] BAFMD,[11,12] nailfold
capillaroscopy,[14] or digital plethysmograph.[14] Long-term
follow-up confirmed the sustained clinical response with a low
rate of relapses (8%) after the end of bosentan therapy. Although
the response rates were numerically better among patients who
gave up smoking, there were no significant differences in the
efficacy outcomes when comparedwith patients whowere unable
to completely abstain from smoking during follow-up. The safety
profile of bosentan therapy was favorable, although ongoing
vigilance for the known adverse reactions is required.
The mechanism through which bosentan acts on TAO is
unclear. One of the key findings in the immunopathogenesis of
this disease is the injury to vascular endothelium, resulting in
activation of the inflammatory response.[4,20,21] Pathohistolog-
ically, TAO lesions are categorized into 3 phases, including acute,
subacute, and chronic, according to the thrombus pattern and the
[20] [2] Olin JW, Shih A. Thromboangiitis obliterans (Buerger’s disease). Curr
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activation and proliferation, and also the presence of immuno-
competent cells, are only seen in acute-type lesions.[20] Endothe-
lial cells play a key role in initiation and perpetuation of the
inflammatory response. Immunoglobulin and complement
deposition, and also CD4+ and CD8+ T lymphocytes, CD20+
B lymphocytes, and S100 positive dendritic cells are found
alongside the lamina elastica interna, which become structurally
altered, but are typically preserved.[4,20,21] An impaired endo-
thelium-dependent vasorelaxation in the peripheral vasculature,
even in the nondiseased limbs, has been observed in TAO.[5–7]
Bosentan has been shown to improve endothelial function in
patients with systemic sclerosis,[22] and, according to the results
of the study of De Haro et al,[11,12] who measured it indirectly by
means of BAFMD, also in TAO patients. Current evidence points
to a greater, or faster, effect of bosentan on the endothelium
compared with its effect as an antifibrotic.[23] Various types of
autoantibodies have been identified in this condition, including
antiendothelial antibodies and agonistic autoantibodies directed
against ET-A-receptor loop 1, potentially promoting vasospasm,
compromising microcirculation, damaging vessel structures, and
inducing proliferative processes.[24,25] In addition, an elevated
serum ET-1 level has been observed in patients with clinically
active disease and necrotic lesions, supporting a possible
mechanistic explanation of the clinical benefit of bosentan in
TAO.[8] ET-1 is a potent endogenous vasoconstrictor that is
mainly secreted by endothelial cells. It acts through 2 types of
receptors: ET-A and ET-B. Bosentan acts as a competitive
antagonist of ET-1 at the ET-A and ET-B receptors. Apart from
vasoconstrictive actions, ET-1 causes fibrosis of vascular cells and
stimulates production of reactive oxygen species.[26,27] It is
claimed that ET-1 induces proinflammatory mechanisms,
increasing superoxide anion production and cytokine secre-
tion.[26,27] A recent study has shown that ET-1 is involved in the
activation of transcription factors such as NF-kB and the
expression of proinflammatory cytokines such as tumor necrosis
factor (TNF)-a, interleukin (IL)-1, and IL-6.[26,27]
When interpreting the results of our study, one needs to
consider the potential limitations derived from its observational
nature, the small sample size, and the lack of multiple-center data.
In addition, we cannot ignore the pitfalls inherent in any
systematic review, including the relatively small number of
identified patients, the retrospective design, and incomplete
follow-up data in some cases. In addition, the high rate of efficacy
observed may be partially explained by the fact that most reports
include cases with a favorable response, whereas cases without
such a response are often not reported.
In summary, our results and those previously reported support
thatbosentanmaybeconsidereda therapeuticoption for treatment
of cases of severe TAO refractory to conventional treatment. We
would like to highlight the excellent clinical response despite the
fact that nearly half of patients continued to smoke. Further
randomized clinical studies with large sample sizes are required to
confirm these preliminary open-label data and establish the length
of therapy and the appropriate use of concomitant medication.References
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